메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Nutromics unveils world-first real-time in vivo multiplexing data at IATDMCT

MELBOURNE, Australia, Oct. 3, 2025 -- Diagnostics company Nutromics has presented the world's first real-time, continuous data on two critical antibiotics - vancomycin and tobramycin - measured simultaneously on the same device in animal models. The breakthrough was unveiled at the International Congress of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) in Singapore. The study, conducted in rats, demonstrated the Nutromics platform's ability to continuously track levels of multiple targets on the one device ('multiplexing'). Both vancomycin, among the most frequently dos
- 김갑성 기자
- 2025-10-03 08:48
MedHub-AI Announces National Reimbursement Approval in Japan for AutocathFFR™

TEL AVIV, Israel, Oct. 3, 2025 -- MedHub-AI today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved national reimbursement for the company's AutocathFFR™ System, effective October 1, 2025. The decision follows regulatory approval by the Pharmaceuticals and Medical Devices Agency (PMDA) earlier this year and marks a significant milestone in expanding access to advanced coronary physiology assessment in Japan. The approval provides physicians and hospitals across Japan with broad access to AutocathFFR, the first fully automated, real-time AI-b
- 김갑성 기자
- 2025-10-03 07:00
HKUST Scientists Reveal Critical Impacts of a Chinese Genetic Risk Factor in Alzheimer's Disease

HONG KONG, Oct. 2, 2025 -- A landmark study conducted by The Hong Kong University of Science and Technology (HKUST) has demonstrated that a genetic variant, TREM2 H157Y, significantly increases the risk of Alzheimer's disease (AD) in individuals of ethnic Chinese descent. The research reveals that this variant confers a risk level comparable to that of the strongest known genetic risk factor for AD, APOE-ε4, and is associated with more rapid clinical progression and more severe neurodegeneration. This is the first in the field to conduct an in-depth family-based clinical case study on
- 김갑성 기자
- 2025-10-02 22:42
SI GROUP BUILDS EMEA DISTRIBUTION NETWORK THROUGH NEW PARTNERSHIP WITH AZELIS

New collaboration will expand SI Group's customer reach complementing its long-standing partnership with Brenntag THE WOODLANDS, Texas, Oct. 2, 2025 -- SI Group, a leading global developer and manufacturer of performance additives, process solutions, pharmaceuticals, and chemical intermediates, announced today a new partnership with Azelis to expand its EMEA distribution network for plastics additives. Effective January 1, 2026, the partnership will extend SI Group's reach and strengthen its ability to serve customers with tailored solutions and local support. SI Group will als
- 김갑성 기자
- 2025-10-02 21:31
Celltrion launches AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in the United States

The AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation was approved in January 2025 by the FDA to treat the same conditions as the reference product ACTEMRA® (tocilizumab) AVTOZMA is Celltrion's fifth immunology biologic and seventh biosimilar approved by the FDA This launch strengthens Celltrion's immunology portfolio beyond tumor-necrosis factor (TNF)-alpha and interleukin (IL)-12 and 23 inhibitors, to include an IL-6 inhibitor, broadening coverage across multiple inflammatory pathways and addressing a wider spectrum of diseases and patient populations I
- 김갑성 기자
- 2025-10-02 20:30
AI Drug Discovery Pioneer, Nanyang Biologics Pte. Ltd., Enters into Business Combination Agreement with RF Acquisition Corp II in US$1.5B Transaction to Pursue Public Listing

[ 메디채널 김갑성 기자 ] Nanyang Biologics Pte. Ltd., together with its subsidiaries (collectively, the "Company", "we" or "NYB"), offers a comprehensive drug discovery platform that integrates the wisdom of traditional medicine with state-of-the-art technologies. Patented Flagship NB-A002 is a First-in-class DNA Damage Response ("DDR") therapeutic product candidate, targeting the previously undruggable target ILF2, inducing synthetic lethality in DDR and Homologous Recombination Deficiency Cancers. Patented Drug-Target Interaction Graph Neural Network (&qu
- 김갑성 기자
- 2025-10-02 19:50
CMEF 2025: 의료 생태계에도 스며든 혁신의 바람

[ 메디채널 김갑성 기자 ] 광저우, 중국 2025년 10월 2일 -- 리드 시노팜 엑시비션즈(Reed Sinopharm Exhibitions)가 주최하는 제92회 중국 국제 의료기기 박람회(CMEF 2025) 추계 전시회가 9월 26일부터 29일까지 광저우 캔톤 페어 콤플렉스(Canton Fair Complex)에서 진행됐다. 약 16만 제곱미터 면적에서 진행된 이 행사에는 20개 국가 및 지역 3천여개 업체가 신제품 1만여 점을 전시했으며, 160여개 국가에서 방문객 12만 명의 눈길을 사로잡았다. 의료 혁신과 고품질 개발을 선도하는 허브라는 CMEF의 지위가 다시 한번 확인되는 순간이었다. CMEF는 지난 40년 동안 제품 출시, 기술 교류, 조달, 학술 협력, 브랜드 구축을 망라하는 최고의 플랫폼으로 등극했다. 올해는 의료 영상, 체외 진단, 수술 로봇, 스마트 헬스케어 등 28개 테마 구역으로 구성되어 연구 개발부터 실제 적용까지 공급망 전체가 주목을 받았다. 전시회 하이라이트 의료 영상 구역: 국산 디지털 심장 단일광자 단층촬영(SPECT)과 대형 평판형 이동식 C-arm 등 '이미징 펄스-
- 김갑성 기자
- 2025-10-02 17:56
Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025

[ 메디채널 김갑성 기자 ] Details of the Phase 3 MASCOT trial investigating amlenetug for the treatment of patients with Multiple System Atrophy (MSA) will be presented at the International Congress of Parkinson's Disease and Movement Disorders® 20251-3 MSA is a rare, rapidly progressing, neurodegenerative disease with no approved treatments available4,5 The innovative design of the pivotal MASCOT trial aims to accelerate drug development for patients living with MSA1 Amlenetug has previously received Orphan Drug Designation (ODD) from the US FDA and the EMA in Europe, in addition to SAKIGAK
- 김갑성 기자
- 2025-10-02 16:41
ExQor Technologies Announces Advancement Toward Clinical Trials for Brain Regenerative Medicine Platform to Treat Alzheimer's Disease

BOSTON, Oct. 2, 2025 -- Addressing Critical Unmet Medical Need ExQor Technologies, a Boston MA based biotechnology company, is preparing for clinical trials for its proprietary brain regenerative medicine platform targeting Alzheimer's disease. Current Alzheimer's therapeutics are limited to slowing cognitive decline, but the company's preclinical data demonstrates something fundamentally different – the ability to reverse brain damage and promote regeneration. An additional trial is planned for frontotemporal dementia, while exploring other conditions affecting cognitive functi
- 김갑성 기자
- 2025-10-02 14:13
World Gym Corporation Advances Global Growth with Mexico MFA and Australia Expansion

Master Franchise Agreement to Bring Minimum of 30 Locations to Mexico; Company Adds Five New Locations Across Australia TAIPEI, Oct. 2, 2025 -- World Gym Corporation (2762.TW) ("World Gym" or the "Company"), the owner of the iconic World Gym brand with over 270 locations worldwide, today announced significant progress in its global growth initiatives, highlighted by a Master Franchise Agreement (MFA) in Mexico and surging growth across Australia. The MFA will bring a minimum of 30 new World Gym facilities to Mexico while the Company has added five new locat
- 김갑성 기자
- 2025-10-02 08:30

이전

41 42 43 44 45 46 47 48 49 50

많이 본 기사

최근기사

2025-11-05_WED

2025-11-04_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 05일 05시 40분